Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients.

Woo YS, Kim W, Chae JH, Yoon BH, Bahk WM.

World J Biol Psychiatry. 2009;10(4 Pt 2):420-5. doi: 10.1080/15622970801910399.

PMID:
18609444
2.

Clozapine and hypertension: a chart review of 82 patients.

Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D.

J Clin Psychiatry. 2004 May;65(5):686-9.

PMID:
15163256
3.
4.

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.

Tollefson GD, Birkett MA, Kiesler GM, Wood AJ; Lilly Resistant Schizophrenia Study Group.

Biol Psychiatry. 2001 Jan 1;49(1):52-63.

PMID:
11163780
5.

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC.

Arch Gen Psychiatry. 2005 Jan;62(1):19-28.

PMID:
15630069
6.

Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.

Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, Wehmeier PM, Hinze-Selch D, Kraus T, Dittmann RW, Pollmächer T.

J Clin Psychopharmacol. 2007 Dec;27(6):662-6.

PMID:
18004133
7.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2003 Feb;160(2):290-6.

PMID:
12562575
8.

A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG.

J Clin Psychiatry. 2008 Feb;69(2):274-85.

PMID:
18232726
9.

Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.

Krakowski MI, Czobor P, Nolan KA.

J Clin Psychopharmacol. 2008 Oct;28(5):485-93. doi: 10.1097/JCP.0b013e3181855cd6.

PMID:
18794642
10.

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.

Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA, Füredi J, Bartko G, Janka Z, Banki CM, Kovacs G, Breier A; Olanzapine HGCK Study Group.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):173-80.

PMID:
14687871
11.

Prolongation of clozapine-induced leukopenia with olanzapine treatment.

Sayin A, Cosar B.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jul;30(5):958-9. Epub 2006 Apr 24.

PMID:
16631295
12.

Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment.

Bachmann CJ, Gebhardt S, Lehr D, Haberhausen M, Kaiser C, Otto B, Theisen FM.

Z Kinder Jugendpsychiatr Psychother. 2012 May;40(3):151-8; quiz 158-9. doi: 10.1024/1422-4917/a000165.

PMID:
22532107
13.

Impact of smoking cessation on psychiatric inpatients treated with clozapine or olanzapine.

Cole ML, Trigoboff E, Demler TL, Opler LA.

J Psychiatr Pract. 2010 Mar;16(2):75-81. doi: 10.1097/01.pra.0000369968.80155.3f.

PMID:
20511731
14.

Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.

Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):417-25.

PMID:
15786516
15.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
16.

Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.

Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B.

Pharmacogenomics J. 2008 Jun;8(3):228-36. Epub 2007 Aug 28.

PMID:
17726453
17.

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.

Lund BC, Perry PJ, Brooks JM, Arndt S.

Arch Gen Psychiatry. 2001 Dec;58(12):1172-6.

PMID:
11735847
18.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2002 Feb;159(2):255-62. Erratum in: Am J Psychiatry 2002 Dec;159(12):2132.

PMID:
11823268
19.

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL.

Arch Gen Psychiatry. 2006 Jul;63(7):721-30.

PMID:
16818861
20.

Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study.

Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Cullen K, Regan J, Kane JM.

J Child Adolesc Psychopharmacol. 2008 Aug;18(4):307-16. doi: 10.1089/cap.2007.0089.

Supplemental Content

Support Center